Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer.

Hiroki InadaHideaki MiyamotoSatoru ShinrikiHisanobu OdaSatoshi NaraharaMotohiro YoshinariKatsuya NagaokaDaiki YoshiiKotaro FukubayashiHiromitsu HayashiHideo BabaKisato NosakaYasuhito Tanaka

Published in: International journal of clinical oncology (2024)

The drug accessibility rate of ICC is high and pemigatinib is effective and well-tolerated in ICC patients harboring FGFR2 gene fusions.

Keyphrases

end stage renal disease
newly diagnosed
copy number
ejection fraction
peritoneal dialysis
papillary thyroid
prognostic factors
case report
genome wide
gene expression
squamous cell carcinoma
dna methylation
patient reported outcomes
childhood cancer